<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191983</url>
  </required_header>
  <id_info>
    <org_study_id>ML25276</org_study_id>
    <nct_id>NCT01191983</nct_id>
  </id_info>
  <brief_title>A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy</brief_title>
  <official_title>A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single arm, open label study will assess the efficacy, safety and tolerability of
      methoxy polyethylene glycol-epoetin beta for the treatment of chronic renal anemia in
      participants with chronic kidney disease (CKD) secondary to diabetes. Participants who are
      not on dialysis and not currently treated with erythropoiesis stimulating agents (ESAs) will
      receive methoxy polyethylene glycol-epoetin beta subcutaneously every 4 weeks (Q4W). The
      starting dose of 1.2 microgram/kilogram (mcg/kg) methoxy polyethylene glycol-epoetin beta
      will be adjusted according to hemoglobin levels. Anticipated time on study treatment is 28
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 13, 2010</start_date>
  <completion_date type="Anticipated">July 19, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 19, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean time taken to achieve target hemoglobin (Hb) levels range (10-12 g/dL) During Efficacy Evaluation Period (EEP)</measure>
    <time_frame>EEP (Week 17 up to Week 24)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hb Concentration Between Baseline and EEP</measure>
    <time_frame>Baseline (Week -2 up to Week 0); EEP (Week 17 up to Week 24)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Maintaining Hb Concentration Within the Target Range (10-12 g/dL) During EEP</measure>
    <time_frame>EEP: (Week 17 up to Week 24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Baseline (Week -2 up to Week 0) to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Red Blood Cell Transfusion During Treatment Period</measure>
    <time_frame>Week 0 up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with anti-epoetin antibodies</measure>
    <time_frame>Baseline (Week-2 up to Week 0) up to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 Health Survey (SF-36) score</measure>
    <time_frame>Week 0 to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Methoxy polyethylene glycol-epoetin beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1.2 mcg/kg methoxy polyethylene glycol-epoetin beta given in monthly doses at each visit. Dose will be measured on the basis of the participants Hb level during the study period. The dose administration will be the nearest possible dose using the prefilled syringes containing 50, 75 and 100 mcg/kg Q4W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxy polyethylene glycol-epoetin beta [Mircera]</intervention_name>
    <description>Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W</description>
    <arm_group_label>Methoxy polyethylene glycol-epoetin beta</arm_group_label>
    <other_name>Mircera, C.E.R.A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic nephropathy

          -  Chronic renal anemia with stage III-IV CKD

          -  Not on dialysis and not expected to require dialysis within the next 6 months

          -  Not receiving any ESA in the 2 months prior to study

          -  Adequate iron status

        Exclusion Criteria:

          -  Transfusion of red blood cells during the previous 2 months

          -  Known or clinical suspicion of pure red cell aplasia

          -  Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any
             constituent of the study medication

          -  Haemoglobinopathy

          -  Significant acute or chronic bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osmania General Hospital; Department of Nephrology</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pushpawati Singhania Research Institute; Nephrology</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indraprastha Apollo Hospitals</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vijayratna Diabetes Diagnosis &amp; Treatment Center</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Delhi Diabetes Centre</name>
      <address>
        <city>Delhi</city>
        <zip>110085</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAX Balaji Hospital</name>
      <address>
        <city>Delhi</city>
        <zip>110092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.Modi's Clinic</name>
      <address>
        <city>Hyderabad</city>
        <zip>500001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPGMER &amp; SSKM Hospital; Rheumatology and Clinical Immunology Centre</name>
      <address>
        <city>Kolkata</city>
        <zip>700 020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Kidney Care Pvt. Ltd., Sushrut Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400 071</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diab Care Centre</name>
      <address>
        <city>Mumbai</city>
        <zip>400076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjeevani Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400097</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahyadri Speciality Hospital</name>
      <address>
        <city>Pune</city>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Care &amp; Research Centre</name>
      <address>
        <city>Pune</city>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2010</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

